Narjust Florez: Interesting and hypothesis provoking research letter in JAMA Oncology
Narjust Florez shared a post on X by JAMA Oncology about a recent paper by Kamran Ahmed et al. published in JAMA Oncology.
Authors: Kamran Ahmed, Priya Kumthekar, Yolanda Pina, Youngchul Kim, Michael Vogelbaum, Hyo Han, Peter Forsyth.
“Interesting and hypothesis provoking research letter in JAMA Oncology with checking it out.
As an editor is a true honor to learn from others and see their efforts to improve care.”
Quoting JAMA Oncology’s post:
“Radiation therapy followed by intrathecal trastuzumab and pertuzumab for HER2+ breast leptomeningeal disease is safe with initial intracranial control results that appear encouraging.”
Sources: Narjust Florez/X and JAMA Oncology/X
Narjust Florez is the Associate Director of the Cancer Care Equity Program and a Thoracic Medical Oncologist at the Dana-Farber Brigham Cancer Center.
She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer. In addition, Dr. Florez founded the Florez Lab in 2019. The laboratory focuses on lung cancer, social justice issues in medicine, and medical education.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023